Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 15/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.51 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6876548 | 1.00 | ADRB3 (0.87) | ADRB3KDM4EALDH1A1GAAMAPT | |
| Hydrochloric Acid SCHEMBL6871484 | 0.99 | ADRB3 (0.86) | ADRB3KDM4EALDH1A1GAAMAPT | |
| Hydrochloric Acid SCHEMBL6871488 | 0.99 | ADRB3 (0.86) | ADRB3KDM4EALDH1A1GAAMAPT | |
| SCHEMBL6864707 | 0.93 | ADRB3 (0.76) | ADRB3KDM4EALDH1A1GAAMAPT | |
| SCHEMBL6864709 | 0.93 | ADRB3 (0.76) | ADRB3KDM4EALDH1A1GAAMAPT | |
| SCHEMBL6864669 | 0.86 | ADRB3 (0.87) | ADRB3ADRB2ADRB1DCTPP1MEN1 | |
| SCHEMBL6864663 | 0.86 | ADRB3 (0.87) | ADRB3ADRB2ADRB1DCTPP1MEN1 | |
| SCHEMBL6870865 | 0.85 | ADRB3 (0.75) | ADRB3ADRB2ADRB1DCTPP1MEN1 | |
| SCHEMBL6870860 | 0.85 | ADRB3 (0.75) | ADRB3ADRB2ADRB1DCTPP1MEN1 | |
| SCHEMBL6864983 | 0.84 | ADRB3 (0.89) | ADRB3ADRB2ADRB1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6821991-B2 | FOR THERAPY OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA (ASSOCIATED WITH OBESITY OR GLUCOSE INTOLERANCE), ATHEROSCLEROSIS, GASTROINTESTINAL DISORDERS, NEUROGENETIC INFLAMMATION, FREQUENT URINATION | WYETH | 2004-11-23 | — | — | US | claimed |
| US-20030176412-A1 | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists | WYETH | 2003-09-18 | — | — | US | claimed |
| US-20020169325-A1 | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists | WYETH | 2002-11-14 | — | — | US | claimed |
| WO-2002006281-A1 | 2-SUBSTITUTED THIAZOLIDINONES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | claimed |
| US-6821991-B2 | FOR THERAPY OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA (ASSOCIATED WITH OBESITY OR GLUCOSE INTOLERANCE), ATHEROSCLEROSIS, GASTROINTESTINAL DISORDERS, NEUROGENETIC INFLAMMATION, FREQUENT URINATION | WYETH | 2004-11-23 | — | — | US | disclosed |
| US-20030176412-A1 | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists | WYETH | 2003-09-18 | — | — | US | disclosed |
| US-6583140-B2 | Useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia, atherosclerosis, gastrointestinal disorders | WYETH | 2003-06-24 | — | — | US | disclosed |
| US-20020169325-A1 | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists | WYETH | 2002-11-14 | — | — | US | disclosed |
| US-6410734-B1 | INSULIN RESISTANCE; HYPOGLYCEMIC AGENTS; ANTICHOLESTEROL AGENTS; GASTROINTESTINAL DISORDERS | WYETH | 2002-06-25 | — | — | US | disclosed |
| WO-2002006281-A1 | 2-SUBSTITUTED THIAZOLIDINONES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169325-A1 | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | ADRB3 2/4885KDM4E 4437/4885ALDH1A1 447/4885 |
| US-20030176412-A1 | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | ADRB3 2/4885KDM4E 4437/4885ALDH1A1 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.